pan-kras inhibitor tln-372
Generic: Pan-KRAS Inhibitor TLN-372
pan-kras inhibitor tln-372: 1 clinical trial tracked.
pan-kras inhibitor tln-372 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pan-kras inhibitor tln-372, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
Primary endpoint: Number of patients experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-372
Interventionalopen240 targetStarted 2025-09Completion 2032-0410 sites · Australia, Canada, Spain, United StatesTreeline Biosciences, Inc.